PARP inhibition in ovarian cancer: what is still missing?

被引：0

作者：

Morotti, Matteo ^{[1
,2
]}

Ghisoni, Eleonora ^{[1
,3
]}

机构：

[1] Ludwig Inst Canc Res, Batiment AGORA, CH-1005 Lausanne, Switzerland

[2] CHUV Ctr Hosp Univ Vaudois, Dept Gynecol, CH-1011 Lausanne, Switzerland

[3] CHUV Ctr Hosp Univ Vaudois, Dept Oncol, Immunooncol Serv, CH-1011 Lausanne, Switzerland

来源：

关键词：

EXPRESSION;

D O I：

10.31083/j.ejgo4301016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：143 / 145

页数：3

共 50 条

[31] Cognitive frailty: What is still missing?
Canevelli, M.
Cesari, M.
[J]. JOURNAL OF NUTRITION HEALTH & AGING, 2015, 19 (03): : 273 - 275
[32] PARP inhibitors in ovarian cancer
Goldlust, Ian S.
Guidice, Elena
Lee, Jung-min
[J]. SEMINARS IN ONCOLOGY, 2024, 51 (1-2) : 45 - 57
[33] PARP Inhibitors in Ovarian Cancer
da Costa, Alexandre
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (16): : 1572 - 1573
[34] PARP Inhibitors for Ovarian Cancer
不详
[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1535): : 200 - 202
[35] PARP INHIBITORS IN OVARIAN CANCER
Calvert, H.
Curtin, N.
Plummer, R.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 23 - 23
[36] Cellular therapies: what is still missing?
Pinkernell, Kai
[J]. KIDNEY INTERNATIONAL, 2011, 79 (11) : 1161 - 1163
[37] PARP inhibitors in ovarian cancer
Ledermann, J. A.
[J]. ANNALS OF ONCOLOGY, 2016, 27 : 40 - 44
[38] PARP inhibitors in ovarian cancer
Franzese, Elisena
Centonze, Sara
Diana, Anna
Carlino, Francesca
Guerrera, Luigi Pio
Di Napoli, Marilena
De Vita, Ferdinando
Pignata, Sandro
Ciardiello, Fortunato
Orditura, Michele
[J]. CANCER TREATMENT REVIEWS, 2019, 73 : 1 - 9
[39] RRM2 inhibition synergizes with PARP inhibitor in ovarian cancer cells
Chen, Chi-Wei
[J]. CANCER RESEARCH, 2023, 83 (07)
[40] Bromodomain inhibition in ovarian cancer and the tumor microenvironment to improve PARP inhibitor response
Wilson, Andrew J.
Hoover, Alyssa
Harris, Whitney
Liu, Esther
Khabele, Dineo
Yull, Fiona
[J]. CANCER RESEARCH, 2018, 78 (13)